startupWhiteLab secures $26M to expand AI-designed gene delivery assetsFrance’s WhiteLab Genomics has raised $26 million (€23 million) in Series B financing to expand experimental validation of its AI-designed gene delivery technologies and build a portfolio of assets … more ➔
EntrepreneurshipFundraising: Why relationships matter more than everIf you ask founders what determines whether they raise capital, most will give you the same answer: great science, compelling clinical data, a large market opportunity and a sensible valuation. For a … more ➔
Alentis TherapeuticsFibrotic tissuesCSL backs Swiss Alentis’ claudin-1 bet with up to $1.6bn dealAustralian biopharma company CSL has entered an exclusive global partnership with Basel-based Alentis Therapeutics to co-develop and co-commercialize lixudebart, an investigational antibody targeting … more ➔
clinical dataGenmab’s Phase 2 data strengthens case for $1.8B ProfoundBio betGenmab’s rinatabart sesutecan (Rina-S) delivered durable responses in a Phase 2 trial in platinum-resistant ovarian cancer, providing encouraging validation for the centerpiece of its $1.8 billion … more ➔
licensingNovartis bets up to $7.8B on Abogen’s mRNA autoimmune therapyNovartis is paying China’s Abogen Biosciences $575 million (€512 million) upfront for global rights to ABO2203, an experimental treatment that uses mRNA to make a B-cell-depleting drug inside the … more ➔
AppointmentsPharming changes CEO, Evotec loses CSO and Nanobiotix hires CFOEvery Friday, The Leadership Edit follows people taking new roles across European biotech and what their moves may tell us about the companies they join. This week: an immediate CEO change at Pharming, … more ➔
clinical dataAmplio’s Phase 1b data hint at better first-line arthritis treatmentAmsterdam-based Amplio Pharma has reported early clinical evidence that its experimental treatment NovoBioJect boosts the active form of methotrexate inside immune cells. The company is seeking about … more ➔
licensingGSK adds liver candidate from Wave RNA partnershipGSK has selected a liver disease drug candidate from its collaboration with Wave Life Sciences for further development, triggering a $12 million (€11 million) milestone payment to the U.S.-based b … more ➔
clinical dataHighlight Therapeutics’ skin cancer injections show promise in Phase 2bSpain’s Highlight Therapeutics reported that its lead candidate, BO-112, met its Phase 2b endpoint in localized basal cell carcinoma, with 61% of evaluable patients achieving a response. more ➔
clinical dataBoehringer, Zealand obesity drug face tolerability questions after Phase 3 successBoehringer Ingelheim’s survodutide delivered average weight loss of up to 13.1% in a Phase 3 trial involving people with overweight or obesity and type 2 diabetes, but gastrointestinal side effects … more ➔
Alentis Therapeutics
